An Exploratory Open-Label, Single Dose, Randomized, Three-Way Crossover Study In Healthy Subjects to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2017
At a glance
- Drugs JNJ 54416076 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Dec 2016 Status changed from recruiting to discontinued.
- 09 Dec 2016 Planned End Date changed from 1 Apr 2017 to 1 Feb 2017.
- 09 Dec 2016 Status changed from not yet recruiting to recruiting.